Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

6 clinical studies listed.

Filters:

Motion Sickness

Tundra lists 6 Motion Sickness clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ENROLLING BY INVITATION

NCT07297862

Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients

The aim of this study is to examine the effects of virtual reality on physiological factors (heart rate, blood pressure) in stroke patients and the psychometric properties of the Virtual Reality Sickness Questionnaire in assessing Motion Sickness resulting from virtual reality use.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2026-03-25

Motion Sickness
ACTIVE NOT RECRUITING

NCT06106256

Three-Axis Wearable Adaptive Vestibular Stimulator

The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.

Gender: All

Ages: 21 Years - 55 Years

Updated: 2026-01-30

1 state

Motion Sickness
ACTIVE NOT RECRUITING

NCT06138613

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

Gender: All

Ages: 18 Years - 75 Years

Updated: 2025-11-21

1 state

Motion Sickness
RECRUITING

NCT05622344

StableEyes With Active Neurofeedback

The investigators have developed a self-administered rehabilitation tool that incrementally guides the user to increase head motion to mitigate motion sickness and enhance postural recovery following centrifugation or unilateral vestibular nerve deafferentation surgery.

Gender: All

Ages: 21 Years - 70 Years

Updated: 2025-11-10

2 states

Vestibular Disorder
Vestibular Schwannoma
Space Motion Sickness
+1
RECRUITING

NCT06892340

Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation

The purpose of this research study is to learn how a wearable nerve stimulation device, the Spark Biomedical's Sparrow Ascent System™, impacts the development of spatial disorientation and/or motion sickness in a healthy population. Spatial disorientation is when there is a "mismatch" between where a person is, and where the sense organs in their body tell them where they are. These sense organs include the inner ear (the vestibular system), the eyes (the visual system), the sense of where one's legs, back, and neck are (proprioceptive system), and one's higher thinking (cognitive centers). If spatial disorientation is severe or occurs in motion-naïve individuals, spatial disorientation can lead to motion sickness. The Sparrow Ascent System™ is a wearable, battery-operated transcutaneous auricular (ear) neurostimulation (tAN) device. This means that it uses electrical pulses to stimulate branches of nerves on and/or around the ear, specifically the "vagus" and "trigeminal" nerves. These nerves are also responsible for your sensation of nausea and your heart rate (vagus nerve), as well as headaches (trigeminal nerve). The Sparrow System utilizes a flexible earpiece with embedded hydrogel electrodes that stick to the skin, the earpiece is disposable after use. This device is already Food and Drug Administration (FDA) approved for use in humans and is safely used for control of symptoms in a variety of other medical conditions, such as opioid withdrawal and acute stress reaction. In this study, we will determine if the Sparrow Ascent System™ impacts the development of spatial disorientation or motion sickness.

Gender: All

Ages: 18 Years - 50 Years

Updated: 2025-08-15

1 state

Motion Sickness
RECRUITING

NCT05886660

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).

Gender: All

Ages: 18 Years - 65 Years

Updated: 2024-05-17

1 state

Motion Sickness, Space
Motion Sickness
Sea Sickness